Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S.
INDIANAPOLIS, Dec. 18, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) for the treatment of infestations caused by New World screwworm larvae (myiasis) in dogs. This is the first FDA conditional approval for a companion animal product to treat New World screwworm.
Credelio Quattro-CA1 now joins Credelio (lotilaner) and Credelio CAT (lotilaner) on the list of companion animal treatment options for New World screwworm, with these other products recently receiving FDA Emergency Use Authorization for the treatment of New World screwworm infestations in dogs and cats, respectively. According to USDA, there have been 14 cases of New World screwworm within 400 miles of the U.S.-Mexico border, all of them related to cattle movementii. With detection reaching as close as 70 miles south of the U.S.-Mexico borderiii, veterinarians and pet owners now have multiple treatment options available should the fly enter the U.S.